Abstract | BACKGROUND: Many studies have reported changes in the hemostatic system in patients with type 1 diabetes in whom coagulation processes predominate over fibrinolytic activity. The aim of this study was to assess some of the hemostatic variables during pregnancy women with in type 1 diabetes. MATERIAL/METHODS: RESULTS: When we compared pregnant diabetic women in the third trimester with those in the first trimester, we observed a statistically significant decrease in the platelet count (172.0+/-9.0 vs 200.6+/-9.8 G/L, P<0.05) and a statistically significant increase in the levels of fibrinogen (3.5+/-0.2 vs 2.9+/-0.2 g/L, P<0.05), tissue plasminogen activator antigen (14.9+/-2.2 vs 4.7+/-0.6 ng/mL, P<0.001), and plasminogen activator inhibitor-1 (17.2+/-2.8 vs 4.0+/-1.0 IU/mL, P<0.001). Similar fibrinogen, tissue plasminogen activator: A, and plasminogen activator inhibitor-1 changes were observed in pregnant women (3.8+/-0.3 vs 2.9+/-0.2 g/L, P<0.05; 7.7+/-0.9 vs 5.2+/-0.3 ng/mL, P<0.05; and 17.6+/-2.1 vs 5.1+/-1.1 IU/mL, P<0.05, respectively). Tissue plasminogen activator antigen was the only variable to significantly increase during the third trimester in pregnant diabetic women with microangiopathy compared with women without microangiopathy (21.0+/-3.2 vs 8.4+/-1.7 ng/mL, P<0.01). CONCLUSIONS:
|
Authors | Agata Bronisz, Danuta Rosc, Marek Bronisz, Wieslaw Szymanski, Roman Junik |
Journal | Medical science monitor : international medical journal of experimental and clinical research
(Med Sci Monit)
Vol. 14
Issue 11
Pg. CR574-9
(Nov 2008)
ISSN: 1643-3750 [Electronic] United States |
PMID | 18971874
(Publication Type: Journal Article)
|
Chemical References |
- Plasminogen Activator Inhibitor 1
- Fibrinogen
- Tissue Plasminogen Activator
|
Topics |
- Adult
- Blood Coagulation
- Diabetes Mellitus, Type 1
(blood, pathology)
- Female
- Fibrinogen
(metabolism)
- Fibrinolysis
- Humans
- Plasminogen Activator Inhibitor 1
(blood)
- Platelet Count
- Pregnancy
- Tissue Plasminogen Activator
(blood)
|